Developed by AVA co-founder, Andrew Eisen, MD, PhD, DRAP is the recombinant form of a unique protein found in Drosophila embryos. DRAP posesses two discrete properties – homology-dependent DNA strand exchange and a resolving, topoisomerase-like activity. AVA has developed techniques to exploit these properties for the introduction of DNA into living systems.
Applications of this technology are broad, and include
- Creation of Genetic Animal Models
- Advancing Biomedical Research
- Biopharmaceutical Manufacturing
- Clinical Applications in Gene Therapy